Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells
Mesenchymal stromal cells (MSCs) have been established as promising candidate sources of universal donor cells for cell therapy due to their contributions to tissue and organ homeostasis, repair, and support by self-renewal and multidifferentiation, as well as by their anti-inflammatory, antiprolife...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2015-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2015/895714 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832554981164580864 |
|---|---|
| author | Natalia Escacena Elena Quesada-Hernández Vivian Capilla-Gonzalez Bernat Soria Abdelkrim Hmadcha |
| author_facet | Natalia Escacena Elena Quesada-Hernández Vivian Capilla-Gonzalez Bernat Soria Abdelkrim Hmadcha |
| author_sort | Natalia Escacena |
| collection | DOAJ |
| description | Mesenchymal stromal cells (MSCs) have been established as promising candidate sources of universal donor cells for cell therapy due to their contributions to tissue and organ homeostasis, repair, and support by self-renewal and multidifferentiation, as well as by their anti-inflammatory, antiproliferative, immunomodulatory, trophic, and proangiogenic properties. Various diseases have been treated by MSCs in animal models. Additionally, hundreds of clinical trials related to the potential benefits of MSCs are in progress. However, although all MSCs are considered suitable to exert these functions, dissimilarities have been found among MSCs derived from different tissues. The same levels of efficacy and desired outcomes have not always been achieved in the diverse studies that have been performed thus far. Moreover, autologous MSCs can be affected by the disease status of patients, compromising their use. Therefore, collecting information regarding the characteristics of MSCs obtained from different sources and the influence of the host (patient) medical conditions on MSCs is important for assuring the safety and efficacy of cell-based therapies. This review provides relevant information regarding factors to consider for the clinical application of MSCs. |
| format | Article |
| id | doaj-art-f89d1f3832af4136ba206a49db0fe140 |
| institution | Kabale University |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2015-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-f89d1f3832af4136ba206a49db0fe1402025-02-03T05:49:57ZengWileyStem Cells International1687-966X1687-96782015-01-01201510.1155/2015/895714895714Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal CellsNatalia Escacena0Elena Quesada-Hernández1Vivian Capilla-Gonzalez2Bernat Soria3Abdelkrim Hmadcha4Department of Stem Cells, Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER), 41092 Seville, SpainNewbiotechnic (NBT), Bollullos de la Mitación, 41110 Seville, SpainDepartment of Stem Cells, Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER), 41092 Seville, SpainDepartment of Stem Cells, Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER), 41092 Seville, SpainDepartment of Stem Cells, Andalusian Centre for Molecular Biology and Regenerative Medicine (CABIMER), 41092 Seville, SpainMesenchymal stromal cells (MSCs) have been established as promising candidate sources of universal donor cells for cell therapy due to their contributions to tissue and organ homeostasis, repair, and support by self-renewal and multidifferentiation, as well as by their anti-inflammatory, antiproliferative, immunomodulatory, trophic, and proangiogenic properties. Various diseases have been treated by MSCs in animal models. Additionally, hundreds of clinical trials related to the potential benefits of MSCs are in progress. However, although all MSCs are considered suitable to exert these functions, dissimilarities have been found among MSCs derived from different tissues. The same levels of efficacy and desired outcomes have not always been achieved in the diverse studies that have been performed thus far. Moreover, autologous MSCs can be affected by the disease status of patients, compromising their use. Therefore, collecting information regarding the characteristics of MSCs obtained from different sources and the influence of the host (patient) medical conditions on MSCs is important for assuring the safety and efficacy of cell-based therapies. This review provides relevant information regarding factors to consider for the clinical application of MSCs.http://dx.doi.org/10.1155/2015/895714 |
| spellingShingle | Natalia Escacena Elena Quesada-Hernández Vivian Capilla-Gonzalez Bernat Soria Abdelkrim Hmadcha Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells Stem Cells International |
| title | Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells |
| title_full | Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells |
| title_fullStr | Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells |
| title_full_unstemmed | Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells |
| title_short | Bottlenecks in the Efficient Use of Advanced Therapy Medicinal Products Based on Mesenchymal Stromal Cells |
| title_sort | bottlenecks in the efficient use of advanced therapy medicinal products based on mesenchymal stromal cells |
| url | http://dx.doi.org/10.1155/2015/895714 |
| work_keys_str_mv | AT nataliaescacena bottlenecksintheefficientuseofadvancedtherapymedicinalproductsbasedonmesenchymalstromalcells AT elenaquesadahernandez bottlenecksintheefficientuseofadvancedtherapymedicinalproductsbasedonmesenchymalstromalcells AT viviancapillagonzalez bottlenecksintheefficientuseofadvancedtherapymedicinalproductsbasedonmesenchymalstromalcells AT bernatsoria bottlenecksintheefficientuseofadvancedtherapymedicinalproductsbasedonmesenchymalstromalcells AT abdelkrimhmadcha bottlenecksintheefficientuseofadvancedtherapymedicinalproductsbasedonmesenchymalstromalcells |